Conference Call Schedules, Disclosures, Partnerships, and Acquisitions - Analyst Notes on Pfizer, Covidien, UnitedHealth Group, Alexion and Abbott

NEW YORK, June 27, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding Pfizer Inc. (NYSE: PFE), Covidien plc (NYSE: COV), UnitedHealth Group Inc. (NYSE: UNH), Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) and Abbott Laboratories (NYSE: ABT). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4194-100free.

--
Pfizer Inc. Analyst Notes
On June 24, 2014, Pfizer Inc. (Pfizer) reported that it will host a live webcast of its conference call with investment analysts on July 29, 2014, at 10:00 a.m. EDT, to provide an update on the Company's results, following the release of its Q2 2014 performance report on the same day. Pfizer stated that the live webcast of the call will be available at its website in the "For Investors" section. The full analyst notes on Pfizer are available to download free of charge at:

http://www.analystsreview.com/Jun-27-2014/PFE/report.pdf

--
Covidien plc Analyst Notes
On June 24, 2014, Covidien plc (Covidien) announced that in accordance with Rule 2.10 of the Irish Takeover Rules, it confirmed that at the close of business on June 23, 2014, its issued share capital, excluding treasury shares, consisted of 451,486,007 ordinary shares, par value $0.20 per share, and added that there were 1,727,873 outstanding restricted share units and 13,674,222 options to purchase ordinary shares granted by the Company. Covidien informed that upon vesting, the holder of each restricted share unit will receive one ordinary share, and the holder of each share option will be able to purchase one ordinary share at the applicable exercise price. The Company confirmed that at the close of business on June 23, 2014, there were outstanding performance share units that entitle holders to receive up to a maximum of 2,194,764 ordinary shares upon vesting, assuming satisfaction of the applicable performance criteria at maximum performance. The full analyst notes on Covidien are available to download free of charge at:

http://www.analystsreview.com/Jun-27-2014/COV/report.pdf

--
UnitedHealth Group Inc. Analyst Notes
On June 24, 2014, UnitedHealth Group Inc. (UnitedHealth Group) announced that its President and CEO, Stephen J. Hemsley, will host a teleconference on Thursday, July 17, 2014, at 8:45 a.m. EDT to discuss the Company's Q2 2014 results, which will be released before the market opens on that day. The Company stated that the call will be webcast live on its website via the Investors page. The replay of the webcast will be available after the live call on the same website until July 31, 2014. The full analyst notes on UnitedHealth Group are available to download free of charge at:

http://www.analystsreview.com/Jun-27-2014/UNH/report.pdf

--
Alexion Pharmaceuticals, Inc. Analyst Notes
On June 23, 2014, Alexion Pharmaceuticals, Inc. (Alexion) announced collaboration with Cincinnati Children's Hospital Medical Center and established Alexion Rare Disease Innovation Fund for the advancement of research in rare diseases. According to the Company, this collaboration will leverage the collective expertise of both parties. Martin Mackay, Ph.D., Executive Vice President and Global Head of Research and Development, Alexion said, "Collaborations between industry and academia are important to drive innovation for patients suffering from rare diseases and we look forward to working with Cincinnati Children's to advance our research programs, which are focused on developing life-transforming therapies for patients with devastating disorders." The Company added that under the agreement, Alexion will have the opportunity to fund selected research programs through the Alexion Rare Disease Innovation Fund, and following their completion, it will have an exclusive option to enter into a licensing agreement for these programs. The full analyst notes on Alexion are available to download free of charge at:

http://www.analystsreview.com/Jun-27-2014/ALXN/report.pdf

--
Abbott Laboratories Analyst Notes
On June 23, 2014, Abbott Laboratories (Abbott) announced a definitive agreement for acquisition of Veropharm by acquiring Limited Liability Company Garden Hills, the holding company that currently owns a controlling interest in Veropharm, for between $395 million to $495 million, depending on Garden Hills' share ownership of Veropharm at the time of close. Abbott stated that Garden Hills currently owns over 80% of Veropharm but is expected to own up to 95% by the time the transaction closes. The Company added that under to the agreement, Abbott will also assume net debt of approximately $136 million. According to the Company, this acquisition will give Abbott a portfolio of medicines that is well suited with its current pharmaceutical therapeutic areas of focus in women's health, central nervous system, cardiovascular, gastroenterology, along with an offering in the field of oncology. Abbott expects the transaction to close in Q4 2014. The full analyst notes on Abbott are available to download free of charge at:

http://www.analystsreview.com/Jun-27-2014/ABT/report.pdf

--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.


===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

AnalystsReview.com

SOURCE Analysts Review